|Bid||5.15 x 800|
|Ask||5.22 x 1200|
|Day's Range||5.08 - 5.37|
|52 Week Range||2.75 - 12.50|
|Beta (3Y Monthly)||5.52|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 9, 2017 - Aug 14, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||16.40|
HENDERSON, NV / ACCESSWIRE / February 13, 2019 / When looking for great growth opportunities to invest in, look no further than the healthcare sector. Healthcare stocks have consistently produced big winners ...
HENDERSON, NV / ACCESSWIRE / February 11, 2019 / Investing in biotech companies can provide investors with huge gains. With that in mind, we're highlighting a few you should know about. One you should ...
Lately, the pharmaceutical companies are trying to use cannabis-based therapies to treat all sorts of medical conditions. Zynerba (NASDAQ:ZYNE) is another contender in this increasingly-crowded field. Whether that's a good or bad thing for Zynerba stock remains to be seen.After all, they appear to have a pretty interesting play within the space. Their ZYN002 drug candidate is, according to the company, "the first and only pharmaceutically-produced CBD formulated as a permeation‑enhanced gel for transdermal delivery".They are running studies on this CBD gel for a variety of conditions. They are investigating treatments for Fragile X, Tourette's, and seizures, among other conditions.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 10 Monster Growth Stocks to Buy for 2019 and Beyond Understanding The Fragile X Syndrome Therapeutic LandscapeFragile X Syndrome is a relatively rare condition occurring in roughly 1 out of every 4,000 boys and 1 out of every 8,000 girls. Researchers believe that the condition is caused by a DNA defect. Fragile X often presents symptoms in children by age 2 including intellectual disability and physical characteristics such as long face and a prominent jaw.It is sometimes a complicated diagnosis as Fragile X can look like other developmental disorders. Many Fragile X children have Attention Deficit Disorder. Additionally, many exhibit features of autism disorders. Furthermore, a significant number of Fragile X patients have frequent seizures.This leads to an interesting position for Zynerba. The company states that there are no approved drug therapies for Fragile X. However, it notes that doctors use various drugs off-label to treat various Fragile X symptoms. That makes sense, as there are treatments for things such as seizures.Directly, as far as competition, Zynerba notes that Neuren Pharmaceuticals, Ovid Therapeutics (NASDAQ:OVID) and Marinus Pharmaceuticals (NASDAQ:MRNS) are all active in the research space seeking a treatment directly for Fragile X syndrome.That's not all. Zynerba has focused on the treatment of seizures in particular. Within that particular space, it faces cannabinoid-based competition on several fronts. GW Pharma (NASDAQ:GWPH), with its more than $4 billion market cap, is targeting this space and is widely thought of as a leader in cannabinoid research.Additionally, Insys (NASDAQ:INSY) is researching CBDs for seizures and infantile spasms as well. So, should Zynerba's ZYN002 be a clinical success, it won't necessarily be the first or best therapy that reaches the market. Why Zynerba Stock Popped RecentlyOn January 28th, Zynerba stock shot up 30% to reach $4.80. In subsequent days, it rallied further, reaching as high as the $6 mark. What happened on Jan. 28 that set the rally in motion? There doesn't appear to be much in the way of hard news, but the company did give a high-profile presentation and it appears this set investor enthusiasm in motion.In this presentation, the company confirmed that things are moving along as planned for its combination Phase 2/3 CONNECT trail for Fragile X syndrome. Zynerba also expects to release results for its Phase 2 trial for developmental and epileptic encephalopathies in the latter half of 2019.To add to that, Zynerba remains in reasonably strong financial position. The company reported $59.8 million in cash as of December 31st, 2018.Given its current burn rate, that should give Zynerba funds to continue its current research through the second half of 2020. While Zynerba will have to raise more funds at some point, it still has plenty of time to deliver its crucial trial results later in 2019 before going back to the market for more money. The CBD FactorIt's difficult to consider ZYNE stock without thinking about the X factor here: investor enthusiasm for marijuana-related stocks. Since late December the Alternative Harvest (NYSEARCA:MJ) marijuana ETF has ripped 50% higher off the lows. Stocks like Aphria (NYSE:APHA) and Canopy Growth (NYSE:CGC) are soaring almost every day.Zynerba itself hadn't participated in this enthusiasm, at least not until recently. However, that may be changing. Recently, famous TV host Jim Cramer talked up so-called "marijuana-adjacent" biotech firms as stocks with big potential in 2019.Cramer said:"These are not pot companies. They are drug companies focused on developing artificial cannabinoids that mimic what cannabis does to your body […] As we get more and more data showing the efficacy of medicinal marijuana, I think more investors will embrace actual medicines that do the same thing as marijuana, but they do it more reliably."With ZYNE stock, you are getting a call option on this thesis playing out later in 2019. Zynerba Stock VerdictI rarely invest in clinical stage biotech companies. It's a difficult industry; far more companies fail than succeed. Be careful with these sorts of stocks and don't invest more than you can afford to lose.That said, Zynerba has an interesting drug candidate, and is certainly positioned in a hot sector of the market. With plenty of cash to make it into mid-2020, and key data coming before then, ZYNE stock has plenty of speculative value for active traders.One upcoming catalyst to watch out for. On February 11th, CEO Armando Anido will be giving a presentation at the 2019 BIO CEO and Investor Conference. With ZYNE stock remaining volatile in recent days, any further data releases or business updates in this presentation could cause a big move in Zynerba shares.At the time of this writing, Ian Bezek held no positions in any of the aforementioned securities. You can reach him on Twitter at @irbezek. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * Are These 7 Dividend Aristocrats ETFs Fit for a King? * 7 of the Best Emerging Markets Stocks to Buy * 5 Gold Stocks That Should Glitter in 2019 Compare Brokers The post Zynerba Stock Is Marijuana-Adjacent Play Worth a Look appeared first on InvestorPlace.
Although the majority of U.S.-based cannabis companies and many foreign ADRs trade over-the-counter, a few marijuana companies are traded on the NASDAQ. Some investors prefer stocks that are listed on the NASDAQ to other exchanges due to their increased liquidity and tighter spreads than the OTC markets.
Zynerba Pharmaceuticals, Inc. (ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Zynerba’s Chief Executive Officer, Armando Anido will present a company overview at the 2019 BIO CEO and Investor conference. The presentation will take place on Monday, February 11, 2019 at 2:00 PM EST at the New York Marriott Marquis. A live webcast of the presentation will be accessible on the Investor Relations page of http://www.zynerba.com.
HENDERSON, NV / ACCESSWIRE / February 4, 2019 / A rough end to 2018 left a host of biotech companies oversold. Many of these companies are starting to rally, and now is the time to research them before ...
HENDERSON, NV / ACCESSWIRE / February 1, 2019 / The biotechnology world is a buzz, 2018's oversold, underperformers are 2019's discounted gems. Below are several biotech stocks that could make you big ...
HENDERSON, NV / ACCESSWIRE / January 30, 2019 / The biotechnology sector has been roaring back strong in 2019. There a few companies that we think you should be researching right now. One company who's ...
NEW YORK, NY / ACCESSWIRE / January 30, 2019 / U.S. markets were mostly down Tuesday on the latest batch of corporate earnings and as investors await details from the Feds' two-day policy meeting. The ...
With headlines popping up left and right, news surrounding these innovative companies in the healthcare industry has worked to attract investors looking for potential opportunities in the space. Premier Health Group (OTC:PHGRF) (CSE:PHGI), OncoCyte Corp (NYSE American: OCX), Neovasc Inc (NVCN), Zynerba Pharmaceuticals Inc (ZYNE) represent four healthcare companies working tirelessly to champion treatment solutions for the betterment of humankind. Premier Health Group (OTC:PHGRF) (CSE:PHGI) is a company focused on developing nuanced approaches that combine human skill-based expertise with state-of-the-art technologies used throughout the healthcare industry to create the best-possible care solutions for their growing patient network.
There's some positive Zynerba Pharmaceuticals news concerning ZYNE stock on Tuesday. Source: Zynerba Pharmaceuticals Investors have likely already noticed that Zynerba Pharmaceuticals (NASDAQ:ZYNE) stock is soaring today. This doesn't have to do with any Zynerba Pharmaceuticals news announcement from the company. Rather, it has to do with options for its CEO. Zynerba Pharmaceuticals CEO Armando Anido has received 160,000 options from the company. These expired on Jan. 24, 2019. It seems that the CEO exercising these options is what is pushing ZYNE stock higher today. InvestorPlace - Stock Market News, Stock Advice & Trading Tips What we don't know is exactly how many of the 160,000 options Anido is exercising. However, the boost to the stock may also be pushing other investors to sell their shares. This includes those that are shorting the stock and see this ramp up as the best potential to make a profit, reports CNA Finance. All these actions in connection to the Zynerba Pharmaceuticals news has the stock flying high on Tuesday. ZYNE stock was up 32% as of noon today. This has the stock trading at around $5.08. That's a major jump over the stock's previous closing price of $3.84 for Monday. * 7 High-Dividend Stocks Yielding More Than 5% (Plus a Bonus) Long-term investors in ZYNE stock are also likely happy about the Zynerba Pharmaceuticals news today. The stock's last six months haven't been its strongest. This has seen it drop 43% from its price of $6.77 that it was sitting at six months ago. While the current price of $5.08 is still short of this, it is good news for investors. ### More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Stocks to Buy With High ESG Momentum * 7 Chinese Stocks to Buy Now * 5 Dow Jones Stocks Under Pressure As of this writing, William White did not hold a position in any of the aforementioned securities. Compare Brokers The post Zynerba Pharmaceuticals News: Why ZYNE Stock Is Soaring Today appeared first on InvestorPlace.
One of the hottest investment trends of the past year has been cannabis stocks, with traders betting that the push toward global marijuana legalization will continue in the U.S. and abroad. For the first ...
JERSEY CITY, N.J., Jan. 22, 2019 /PRNewswire/ -- SCYNEXIS, Inc. (SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced the appointment of Armando Anido to its Board of Directors. Mr. Anido currently serves as Chairman and Chief Executive Officer of Zynerba Pharmaceuticals (ZYNE), a role he has held since October 2014.
Investors need to pay close attention to Zynerba Pharmaceuticals (ZYNE) stock based on the movements in the options market lately.
Now that one cannabis-based drug has won FDA approval, a wide range of drugmakers, from small biotech stocks to giant pharma firms, are exploring the substance to treat a host of maladies.
Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) has released 12-month clinical data that describes the lifelong impact of ZYN002 on developmental and responsive symptoms of Fragile X syndrome. In a poster for the presentation in the 57th annual meeting, Professor Steven Siegel gives the presentation of the 12-month data of the second phase of the clinical trial of […] The post Zynerba Gives Clinical Update, Lifelong Impact Of ZYN002 appeared first on Market Exclusive.
Here's a roundup of top developments in the biotech space over the last 24 hours. No biotech stock hit 52-week high in Wednesday's session. Down In The Dumps (Biotech stocks hitting 52-week lows on Dec. ...
Zynerba Pharmaceuticals, Inc. (ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, is reporting new 12-month open label clinical data describing the long term impact of ZYN002 on emotional and behavioral symptoms of Fragile X Syndrome (FXS) in a poster presentation at the 57th Annual Meeting of the American College of Neuropsychopharmacology. In a poster entitled, “Transdermal Cannabidiol (CBD) Gel for the Treatment of Fragile X Syndrome (FXS),” Steven Siegel, M.D., Ph.D., Professor and Chair of the Department of Psychiatry and the Behavioral Sciences at the Keck School of Medicine, University of Southern California, is presenting new 12-month data from the open label Phase 2 FAB-C (Treatment of Fragile X Syndrome Anxiety and Behavioral Challenges with CBD) trial of ZYN002 in children and adolescents with FXS.
Zynerba Pharmaceuticals, Inc.'s (NASDAQ:ZYNE): Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company’s loss has recently broadened since it announced a -US$32.0m loss in the full Read More...
NEW YORK, Nov. 23, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
HENDERSON, NV / ACCESSWIRE / November 21, 2018 / Moderna and Synthorx's huge IPOs show biotech point to a strong biotech sector that should continue a bull run heading into the new year. CBD based biotechs ...
Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE ) have dropped by about 12 percent since the company reported third-quarter results Nov. 8. Analysts at HC Wainwright and Canaccord Genuity consider the sell-off ...